PYNKF
Perimeter Medical Imaging AI, Inc.·Healthcare
0.23
8.000%(−0.02)
Market ClosedLast Updated: — ET
52W L: $0.1152W H: $0.53
PYNKF NEWS
seekingalpha.com
Mar 31
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q4 2025 Earnings Call Transcript
Perimeter Medical Imaging AI, Inc. (PINK:CA) Q4 2025 Earnings Call Transcript
prnewswire.com
Mar 31
Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance
Conference Call/Webcast Today at 5:00 pm ET TORONTO and DALLAS, March 31, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported preliminary unaudited financial results for its fourth quarter and full year ended December 31, 2025, and provided a corporate update. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.
prnewswire.com
Mar 23
Perimeter Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 31st; Provides Corporate Update
TORONTO and DALLAS, March 23, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its fourth quarter and full year 2025 financial and operating results after market close on Tuesday, March 31, 2026. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.
prnewswire.com
Mar 3
Perimeter Medical Imaging AI's 'Claire' Becomes First FDA-approved AI-Enabled Imaging Device for Breast Cancer Surgery
Claire demonstrated a statistically significant reduction in patients with residual cancer post-surgery compared to the standard of care alone Social Capital's Chamath Palihapitiya highlights Claire as a compelling example of how AI innovation can drive meaningful medical impact Company plans nationwide launch of real-time AI tool for margin assessment designed to help surgeons reduce repeat surgeries TORONTO and DALLAS, March 3, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration ("FDA") premarket approval ("PMA") for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment. The technology received Breakthrough Device designation from the FDA and is designed to enhance surgeons' ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.
prnewswire.com
Feb 17
Perimeter Announces Grant and Cancellation of Stock Options
TORONTO and DALLAS, Feb. 17, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announces its intention to enter into cancellation agreements with certain employees and consultants of the Company, pursuant to which it will cancel and grant stock options to such employees and consultants. The Company intends to enter into such cancellation agreements, pursuant to which it will cancel up to 2,175,619 previously issued stock options (the "Original Options"), exercisable at prices ranging from C$0.38 to C$2.85, granted to 27 employees and consultants of the Company.
